Nautilus Biotechnology receives Nasdaq bid price deficiency notice; has until Oct 28, 2025 to regain compliance.

Nautilus Biotechnology, Inc.

Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.
Has 180 calendar days (until October 28, 2025) to regain compliance; stock continues trading.
To cure, closing bid price must be at least $1.00 for ten consecutive business days during the Compliance Period.
If not compliant, may qualify for additional 180 days by transferring to Nasdaq Capital Market and meeting other requirements.
No immediate delisting; company evaluating options but no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.